Amyloid β-Protein (25-35) trifluoroacetate salt

Modify Date: 2024-01-01 20:59:59

Amyloid β-Protein (25-35) trifluoroacetate salt structure	Common Name	Amyloid β-Protein (25-35) trifluoroacetate salt
	CAS Number	131602-53-4	Molecular Weight	1060.27000
	Density	1.249g/cm3	Boiling Point	1517.336ºC at 760 mmHg
	Molecular Formula	C₄₅H₈₁N₁₃O₁₄S	Melting Point	N/A
	MSDS	Chinese USA	Flash Point	871.453ºC

Use of Amyloid β-Protein (25-35) trifluoroacetate salt

Amyloid beta-peptide(25-35) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.

Name	Amyloid β-Protein Fragment 25-35
Synonym	More Synonyms

Description	Amyloid beta-peptide(25-35) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
Related Catalog	Signaling Pathways >> Neuronal Signaling >> Amyloid-β Peptides Research Areas >> Neurological Disease Peptides
In Vitro	The amino acid sequence of Aβ(25-35) peptide is NH2-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-COOH, where the first Gly represents the amino acid 25 and the last Met represents the amino acid 35. Amyloid beta-peptide(25-35) is also investigated in gel state for the first time. Comparative studies are also carried out using vibrational absorption and ECD. The conformational preference of Aβ(25-35) peptide film is also investigated using vibrational absorption and VCD spectroscopy[1]. Amyloid beta-peptide(25-35) induces apoptotic effects on isolated brain mitochondria and the redox state of methionine-35, plays a key role in the induction of programmed cellular death pathways and toxic events[2].
In Vivo	Rats are injected with Aβ25–35 peptide intracerebroventricularly and compound Danshen (CDS) are subsequently administered once daily for 23 days. Rats’ behavior is monitored using Morris water maze and passive avoidance. Real time PCR and Western blotting are used in determining amyloid precursor protein (APP), β-site APP cleaved enzyme-1(BACE1), Presenilin-1 (PS1), Insulin-degrading enzyme (IDE) and neprilysin (NEP) in hippocampus. The Alzheimer' s disease (AD) model group present with spatial learning and memory impairments. CDS and donepezil administration significantly ameliorate the Aβ25–35 peptide-induced memory impairment in both Morris water maze (P < 0.05) and passive avoidance task (P < 0.01) compared to the AD model group[3].
Cell Assay	Cell viability is determined by a modified MTS assay, which is based on the conversion of Tetrazolium salt by mitochondrial dehydrogenase to a formazan product spectrophotometrically measurable at 490 nm. PC12 cells are plated in 96-well plates at a density of 10 000 cells/well and maintained for 16 h in complete medium. Cells are then incubated in the absence (control) and presence of 40 μM Aβ(31-35) and Aβ(25-35) with reduced, oxidized and norleucine-substituted methionine-35 staurosporine 10 μM is used as positive control of 100% of cellular death. After 48 h of peptide-incubation, 20 μL of MTS reagent (2.0 mg/mL) is added to each well. The cells are then incubated for 30-45 min at 37 °C in a 5% CO2 incubator. The reaction is stopped by adding 25 μL of 10% SDS. The plates are read with a microplate reader at 490 nm. Each data point is obtained using a triplet-well assay[2].
Animal Admin	Rats[3] Fifty-four Male Sprague-Dawley rats (2 months old, 300-350 g) are used. Amyloid beta-peptide(25-35) is dissolved in sterile distilled water at a concentration of 1 mg/mL as a stocking solution. Animals are infused with 5 μL/side of sterile distilled water (control), aggregated Aβ25-35 (2 μg/μL), into bilateral cerebral lateral ventricles at a rate of 1 μL/min; the needle is left in place for 5 min. Then the needles are removed and rats are kept on a warm pad until they are awakened. To determine the neuroprotective effect on AD rats, the Aβ25-35 treated rats are treated with CDS of different doses and Donepezil once daily for 23 days (including duration of behavior test). Experiment is performed to test the effect of CDS on Aβ25-35-induced memory impairment using Morris water-maze and step-through passive avoidance tasks. Specifically, all of the rats are randomly divided into 6 groups for the experiment: (a) Vehicle 1 (for Aβ25-35)+vehicle 2 (for CDS and Donepezil), (b) Aβ25-35+vehicle 2, (c) Aβ25-35+CDS (130 mg/kg), (d) Aβ25-35+CDS (260 mg/kg), (e) Aβ25-35+CDS (520 mg/kg), (f) Aβ25-35+Donepezil (0.5 mg/kg). One day after cerebroventricular microinfusions of Aβ25-35 (10 μg/side) or its vehicle, rats are treated (i.g.) with CDS or Donepezil or vehicle 2, once daily for 14 days prior to the beginning of Morris water maze, followed by passive avoidance task.
References	[1]. D'Ursi AM, et al. Solution structure of amyloid beta-peptide (25-35) in different media. J Med Chem. 2004 Aug 12;47(17):4231-8. [2]. Clementi ME, et al. Abeta(31-35) and Abeta(25-35) fragments of amyloid beta-protein induce cellular death throughapoptotic signals: Role of the redox state of methionine-35. FEBS Lett. 2005 May 23;579(13):2913-8. [3]. Liu M, et al. Cognitive improvement of compound danshen in an Aβ25-35 peptide-induced rat model of Alzheimer's disease. BMC Complement Altern Med. 2015 Oct 23;15:382.

Density	1.249g/cm3
Boiling Point	1517.336ºC at 760 mmHg
Molecular Formula	C₄₅H₈₁N₁₃O₁₄S
Molecular Weight	1060.27000
Flash Point	871.453ºC
Exact Mass	1059.57000
PSA	468.96000
LogP	1.05840
Vapour Pressure	0mmHg at 25°C
Index of Refraction	1.544
Storage condition	-20°C

Personal Protective Equipment	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
RIDADR	NONH for all modes of transport
WGK Germany	3

Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides.

Science 250 , 279, (1990)

The amyloid beta protein is deposited in the brains of patients with Alzheimer's disease but its pathogenic role is unknown. In culture, the amyloid beta protein was neurotrophic to undifferentiated h...

Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells.

PLoS ONE 9(10) , e111536, (2014)

Alzheimer's disease (AD) is a chronic progressive neurodegenerative disorder. As the most common form of dementia, it affects more than 35 million people worldwide and is increasing. Excessive extrace...

Mesenchymal stem cells can prevent alterations in behavior and neurogenesis induced by Aß25-35 administration.

J. Mol. Neurosci. 55(4) , 1006-13, (2015)

Mesenchymal stem cells (MSCs) are known to enhance neurogenesis in the dentate gyrus, as well as to modulate immune cell activity and inflammation. Easily obtained and expanded from the bone marrow an...

Amyloid β-peptide (25-35) (human)

Amyloid beta-peptide(25-35)